STOXPO
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
STOXPO
No Result
View All Result
Home Healthcare Pharmaceuticals
drugs-3

MIRA Pharmaceuticals Advances Ketamir-2: A Safe Step Forward in Neuropathic Pain Treatment

byLuca Blaumann
December 10, 2024
in Pharmaceuticals, Small-Cap
Reading Time: 4 mins read
Share on TwitterShare on LinkedIn

Favorable safety results pave the way for Phase 1 human trials in early 2025, offering hope for millions seeking non-addictive pain relief solutions

MIRA Pharmaceuticals (MIRA), a preclinical-stage pharmaceutical company, has announced a critical advancement in its development of Ketamir-2, a novel oral ketamine analog designed to treat neuropathic pain. Recent safety studies affirm the drug’s strong safety profile, enabling the company to progress toward Phase 1 human trials in early 2025.

A Milestone in Neuropathic Pain Drug Development

“This milestone reflects our commitment to advancing Ketamir-2 as a safe and effective treatment for neuropathic pain,” said Erez Aminov, CEO and Chairman of MIRA Pharmaceuticals. “Our focus on safety positions us to attract strategic partnerships or pursue potential mergers and acquisitions as we move forward.”

The findings mark a significant step for MIRA, as safety concerns account for nearly 40% of drug failures during clinical development. By addressing this critical challenge early, the company reduces risk and strengthens its case for regulatory approval.

Preclinical Data Highlights Ketamir-2’s Safety

Comprehensive preclinical studies revealed no significant safety concerns for Ketamir-2 across key physiological systems:

  • Cardiovascular Safety: No adverse effects at therapeutic doses in canine studies.
  • Central Nervous System (CNS): Favorable outcomes in rats, with no significant changes at therapeutic doses. High-dose effects were limited, transient, and non-disruptive.
  • Respiratory Function: No respiratory-related effects in rats, even at higher doses.
  • 14-Day Toxicology: Ketamir-2 was well-tolerated at daily doses up to 200 mg/kg in dogs.
  • Ames Test: The drug was confirmed as non-mutagenic, underscoring its safe profile.

These results collectively validate Ketamir-2’s potential as a non-addictive alternative for managing neuropathic pain, a condition that affects millions of people worldwide.

The Road to Phase 1 Human Trials

Building on the success of these preclinical studies, MIRA aims to launch its Phase 1 human trials in the first quarter of 2025. These trials will assess Ketamir-2’s safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy participants.

Notably, the trials will incorporate a battery of pain and psychosis tests, offering valuable insights into the drug’s therapeutic effects. Initial results are anticipated by the second quarter of 2025.

Following Phase 1, the company plans to initiate a Phase IIa proof-of-concept study in late 2025. This study will focus on patients with neuropathic pain, with results expected in early 2026.

Addressing an Urgent Medical Need

Neuropathic pain remains a challenging condition to treat, as many existing therapies carry risks of addiction or intolerable side effects. Ketamir-2’s development represents a potential paradigm shift in managing this condition, offering hope to patients seeking safer, more effective options.

Dr. Itzchak Angel, MIRA’s Chief Scientific Advisor, emphasized the broader implications of this development:
“This is a pivotal moment for both MIRA Pharmaceuticals and the millions of patients who suffer from neuropathic pain. Ketamir-2 holds the promise of being a groundbreaking treatment, addressing a significant unmet medical need with its strong safety profile and potential efficacy.”

Financial and Strategic Strength

MIRA’s financial position further bolsters its ability to achieve clinical milestones. The company is actively exploring non-dilutive funding opportunities to accelerate development and enhance Ketamir-2’s therapeutic impact.

By demonstrating Ketamir-2’s safety and positioning it for clinical success, MIRA not only advances its mission but also strengthens its appeal to potential partners and investors.

MIRA Pharmaceuticals’ progress with Ketamir-2 underscores the company’s commitment to addressing critical gaps in neuropathic pain management. With a strong safety profile validated through rigorous preclinical testing, the company is poised to move confidently into human trials.

As the global demand for non-addictive pain treatments grows, Ketamir-2’s development represents a beacon of hope for millions. MIRA’s innovative approach and strategic focus position it as a leader in this transformative field of medicine.

Clickhereto read the original press release.

You might like this article:Mondelez Eyes Hershey in Potential Blockbuster Deal

Tags: BreakingGrowthMIRAMoversNewspharmaStock Market
Previous Post

Mondelez Eyes Hershey in Potential Blockbuster Deal

Next Post

Oracle Shares Tumble as Revenue Falls Short, Cloud Competition Intensifies

Related Posts

investing

Dragonfly Energy Secures Nevada Tech Hub Funding to Strengthen Lithium Battery Innovation

byLuca Blaumann
October 3, 2025
0

$300,000 award to support modernization, workforce training, and growth in Nevada’s clean energy economy Dragonfly Energy Holdings (DFLI), the Reno-based...

investing

Chijet Secures Up to $1 Billion in Expanded Private Placement

byLuca Blaumann
October 1, 2025
0

Automaker pivots toward digital asset custody with strong institutional backing Chijet Motor Company (CJET) announced a major milestone on Friday,...

drugs-4

Kenvue Rebounds After Tylenol Autism Claims Spark Market Jitters

byLuca Blaumann
September 23, 2025
0

Analysts cite lack of new scientific evidence as shares recover from record low Kenvue (KVUE) shares rose 6% on Tuesday,...

Next Post
investing

Oracle Shares Tumble as Revenue Falls Short, Cloud Competition Intensifies

Latest News

Verizon Partners with AST SpaceMobile to Deliver Space-Based Cellular Coverage

Envoy Medical Advances to Final Stage of FDA Trial for Fully Implanted Cochlear Implant

Tech Rally Lifts S&P 500 and Nasdaq as AMD Soars on OpenAI Deal

AMD Soars 25% After Landmark AI Chip Deal With OpenAI

Dragonfly Energy Secures Nevada Tech Hub Funding to Strengthen Lithium Battery Innovation

Based on Your Interest

Rivian Electric Pickup Truck
Auto Manufacturers

Rivian Cuts Delivery Forecast Amid Loss of EV Tax Credits

October 2, 2025
Electrical Equipment

KULR Launches Next-Generation Battery Management System for Space and Defense

October 2, 2025
investing
Auto Manufacturers

Chijet Secures Up to $1 Billion in Expanded Private Placement

October 1, 2025

Recommended

Large-Cap

Nike Surprises Wall Street With Strong Q1 Results

September 30, 2025
Entertainment

Fubo Shareholders Approve Disney Merger With Hulu Live TV

September 30, 2025
Brokerages

Robinhood Surges on Prediction Market Growth

September 30, 2025
Large-Cap

Nike Faces Steep Profit Decline as Q1 Results Loom

September 29, 2025
Biotechnology

Drugmakers Gain as Markets Digest Trump’s Proposed 100% Pharma Tariffs

September 26, 2025
Stoxpo

Follow us on social media:

Highlights

  • Verizon Partners with AST SpaceMobile to Deliver Space-Based Cellular Coverage
  • Envoy Medical Advances to Final Stage of FDA Trial for Fully Implanted Cochlear Implant
  • Tech Rally Lifts S&P 500 and Nasdaq as AMD Soars on OpenAI Deal
  • AMD Soars 25% After Landmark AI Chip Deal With OpenAI
  • Dragonfly Energy Secures Nevada Tech Hub Funding to Strengthen Lithium Battery Innovation

Category

  • Blog
  • Communication Services
    • Entertainment
    • Internet
    • Telecommunications
  • Companies
    • Large-Cap
    • Mega-Cap
    • Micro-Cap
    • Mid-Cap
    • Small-Cap
  • Consumer Cyclical
    • Auto Manufacturers
    • Casinos & Gambling
    • Ground Transportation
    • Hospitality
      • Casinp
      • Resorts & Lodging
      • Restaurants
      • Travel
        • Airlines
    • Retail
    • Textiles, Apparel & Luxury Goods
  • Consumer Defensive
    • Beverages
    • Discount Stores
    • Distributor
    • Ecommerece
    • Electrical Equipment
    • Foods
    • Household & Personal Products
    • Leisure Products
    • Tobacco
  • Contributions
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Economy
  • Energy
    • Electric
    • Oil & Gas
    • Renewables
  • Financial Services
    • Asset Management
    • Banks
    • Brokerages
    • Credit Services
    • Insurance
  • Healthcare
    • Biotechnology
    • Medical Devices
    • Pharmaceuticals
  • Industrials
    • Aerospace & Defense
    • Construction
    • Industrial Machinery
  • Materials
    • Building Materials
    • Chemicals
    • Gold
    • Mining
    • Silver
    • Steel
  • Q&A's
  • Real Estate
  • Technology
    • Artificial Intelligence
    • Computer Hardware
    • Consumer Electronics
    • Cybersecurity
    • IT Services
    • Semiconductors
    • Software
  • Utilities

Latest News

Verizon Partners with AST SpaceMobile to Deliver Space-Based Cellular Coverage

October 8, 2025
chemistry-2

Envoy Medical Advances to Final Stage of FDA Trial for Fully Implanted Cochlear Implant

October 7, 2025
investing

Tech Rally Lifts S&P 500 and Nasdaq as AMD Soars on OpenAI Deal

October 6, 2025
  • About
  • Privacy Policy
  • Contact

© 2024 All Rights Reserved: STOXPO.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More

In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information

Accept Cookie Settings
Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
  • Always Active
    Necessary
    Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
  • Marketing
    Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
  • Analytics
    Analytics cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
  • Preferences
    Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
  • Unclassified
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
Cookie Settings

Do you really wish to opt-out?

No Result
View All Result
  • Latest News
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Technology
    • Software
    • Semiconductors
  • Crypto
    • Bitcoin
    • Ethereum
    • Altcoins
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions

© 2024 All Rights Reserved: STOXPO.